ClinConnect ClinConnect Logo
Search / Trial NCT05613218

Oxygen Targets in Acute Heart Failure With Pulmonary Congestion

Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Nov 4, 2022

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Acute Heart Failure Pulmonary Edema Oxygen Pulmonary Congestion

ClinConnect Summary

This clinical trial is studying the best way to provide oxygen to patients who are hospitalized with acute heart failure and experiencing difficulty breathing due to fluid buildup in the lungs (known as pulmonary congestion). The trial will compare two different oxygen strategies: one group will receive enough oxygen to keep their levels at 96%, while the other group will aim for a lower target of 90%. This research aims to find out which oxygen target is more effective for helping patients in this situation.

To be eligible for the trial, participants must be at least 18 years old and have recently experienced worsening shortness of breath, along with a low oxygen level (below 92%). They should also show signs of fluid in the lungs through clinical exams or imaging tests. Participants will be randomly assigned to one of the two oxygen groups using a special machine that delivers oxygen, ensuring that neither the patients nor the healthcare team knows which group they are in. The study will include 122 patients, and those who qualify can expect close monitoring and care during their hospital stay. It's important to know that this trial is currently recruiting patients and aims to help improve treatment strategies for acute heart failure.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years
  • 2. Acute (within minutes to days) onset or worsening of subjective dyspnea
  • 3. Oxygen saturation \<92% (on arterial blood gas) or need of oxygen
  • 4. At least one of the following clinical or radiological signs of congestion:
  • 1. Pulmonary rales 2. Chest X-ray or CT with pulmonary congestion 3. Lung ultrasound with multiple B-lines
  • Exclusion Criteria:
  • 1. More than 4 hours from hospital admission to randomization
  • 2. Suspected infection or sepsis
  • 3. Known severe pulmonary disease
  • 4. Systolic blood pressure \<90 mmHg

About Copenhagen University Hospital, Hvidovre

Copenhagen University Hospital, Hvidovre, is a leading clinical research institution in Denmark, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent academic hospital affiliated with the University of Copenhagen, it integrates cutting-edge research with clinical practice, fostering innovation in various medical fields. The hospital is dedicated to conducting rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines, while prioritizing patient safety and welfare. With a multidisciplinary approach and access to diverse patient populations, Copenhagen University Hospital, Hvidovre plays a vital role in translating research findings into effective treatments and therapies.

Locations

Copenhagen, Capital Region, Denmark

Copenhagen, , Denmark

Patients applied

0 patients applied

Trial Officials

Jens Hove, MD, PhD

Study Chair

Copenhagen University Hospital Amager-Hvidovre Department of Cardiology

Johannes Grand, MD, PhD

Principal Investigator

Copenhagen University Hospital Amager-Hvidovre Department of Cardiology

Ida Taraldsen, MD

Study Director

Copenhagen University Hospital Amager-Hvidovre Department of Cardiology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials